Navigation Links
Clinical Site Services Expands to Provide Global Patient Enrollment Services to Rest-of-World
Date:5/3/2011

GLEN BURNIE, Md., May 3, 2011 /PRNewswire/ -- Answering the need for global, site-focused enrollment support, Clinical Site Services (CSS), a leader in the patient enrollment industry, announces the expansion of its services to include global enrollment planning and implementation on a local, site-centric level.

"The extension of our worldwide presence is an important step that will allow us to assist sponsors with their global patient enrollment needs," says Chris Trizna, President of Clinical Site Services. "To date, we have been quite successful in delivering patient enrollment solutions to investigative sites and sponsors in North America; this expansion means that sponsors no longer need to seek out different patient recruitment partners for North American and Rest-of-World needs."

The CSS London-based office, headed up by industry executive Richard Anderson, will tap into professionals who have more than 20 years of experience in the life science, healthcare and patient recruitment industries. They will be able to implement patient enrollment and retention campaigns which are solely based in global markets, or as an adjunct to North American endeavors.

As with all CSS North American campaigns, the global programs will offer customized clinical research support and expertise. Through Local Enrollment Specialists, regional experts who have detailed knowledge of each country's regulatory provisions, CSS will provide site assessments, chart reviews, ethics committee submissions, local patient enrollment expertise, planning and implementation in more than 40 countries.

"This is an exciting new initiative. For the first time a patient enrollment provider can support sites at local level in over 40 countries," stated Richard Anderson, CSS Director of Global Patient Enrollment. "The teams will be working with the sites to help optimize their patient enrollment programs, maximizing enrollment and ROI."

All international endeavors will be centrally managed by CSS's project team.

"It all comes down to enrollment. Generating interest is important, but it's what happens after that," shared Trizna. "Sites are the only ones who can enroll patients. Successful sites consistently meet their enrollment goals. We are poised to support them with enrollment planning and implementation."

About Clinical Site Services

Founded in 2005, Clinical Site Services (CSS) is a global enrollment performance company that increases enrollment and retention for pharma, CROs and investigative sites through a site-focused approach and adaptive enrollment process.

US Contact:
Jennifer Whitlock
VP/Director of Marketing
Clinical Site Services
P: 410-793-1067
F: 410-553-0087
jwhitlock@clinicalsiteservices.com
http://www.ClinicalSiteServices.com

UK Contact:
Richard Anderson
Director of Global Patient Enrollment
Clinical Site Services
P: +44 020 8347 9935
randerson@clinicalsiteservices.com
http://www.ClinicalSiteServices.com

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Clinical Site Services
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
2. Omnicare Clinical Research Acquired by Nautic Partners, LLC
3. Stanford and SanBio Announce a Clinical Trial of Cell Therapy for Stroke Disability
4. ACT Files European Clinical Trial Application for Phase 1/2 Study Using Embryonic Stem Cells to Treat Macular Degeneration
5. Tissue Genesis Begins FDA-Approved Clinical Trial
6. ClearCanvas Releases First Commercial Version of Popular Clinical Radiology Workstation; PACS and RIS to Follow
7. Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
8. S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies
9. ePharmaSolutions Launches New Application to Streamline Single Sign-On and User Account Provisioning for Sponsors Using Multiple Clinical Trial Technologies
10. Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
11. Tolerx Presents Preclinical Data on Novel Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... three months ended December 31, 2016. SQI ... diagnostics company that develops and commercializes proprietary technologies and products ... ... commercial milestones achieved in fiscal 2016," said Andrew Morris ...
(Date:2/21/2017)... ... ... The medical potential of stem cells is both extensive and astounding, and ... their differentiating characteristics. Stem cells are unique as the have the potential to renew ... tissue or organic-specific cells with special functions. , Stem cell therapy in the ...
(Date:2/21/2017)... 21, 2017  Lexus, a returning partner of the Amgen ... and exclusive automobile partner of the men,s and women,s events for ... The 2017 Amgen Tour of California will ... of the best professional cycling teams in the world racing from ... four-day Amgen Breakaway from Heart Disease TM Women,s ...
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... ... to announce that it has been approved for full, active membership in the ... Dallas, Texas, was founded by Chief Executive Officer Jeff Olson in ...
Breaking Biology Technology:
(Date:2/13/2017)... , Feb. 13, 2017 Former 9/11 Commission ... Judiciary Committee, Janice Kephart of Identity Strategy ... Donald Trump,s "Executive Order: Protecting the Nation ... 27, 2017):  "As President Trump,s ,Travel Ban, ... has now essentially banned the travel ban, it is ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global synthetic-biology ... $11.4 billion by 2021, growing at a compound annual growth ... An overview of the global markets for synthetic biology. - ... for 2016, and projections of compound annual growth rates (CAGRs) ...
(Date:2/7/2017)... 7, 2017 Ipsidy Inc. ( ... [OTC: IDGS], ("Ipsidy" or the "Company") a provider of ... services, is pleased to announce the following changes as ... Effective January 31, 2017, Philip D. Beck ... and President.  An experienced payment industry professional and public ...
Breaking Biology News(10 mins):